Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
This practice is not approved by the U.S. Food and Drug Administration (FDA). "Health care clinicians do not typically ...
Global health highlights include a court pausing a generic version of a heart drug, Novo Nordisk's weight loss trial success, ...
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.